Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G.
Montalban-Bravo G, et al. Among authors: soltysiak ka.
Blood Adv. 2020 Feb 11;4(3):482-495. doi: 10.1182/bloodadvances.2019001101.
Blood Adv. 2020.
PMID: 32027746
Free PMC article.